140 related articles for article (PubMed ID: 18334748)
1. Generation and characterization of a therapeutic human antibody to melanoma antigen TYRP1.
Patel D; Balderes P; Lahiji A; Melchior M; Ng S; Bassi R; Wu Y; Griffith H; Jimenez X; Ludwig DL; Hicklin DJ; Kang X
Hum Antibodies; 2007; 16(3-4):127-36. PubMed ID: 18334748
[TBL] [Abstract][Full Text] [Related]
2. Cell binding and tumor inhibiting functions of a new antihuman melanoma murine monoclonal antibody.
Abdel-Wahab Z; Darrow T; Vervaert CE; Crowley NJ; Seigler HF
Mol Biother; 1991 Sep; 3(3):163-9. PubMed ID: 1768367
[TBL] [Abstract][Full Text] [Related]
3. Enhanced suppression of melanoma tumor growth and metastasis by combined therapy with anti-VEGF receptor and anti-TYRP-1/gp75 monoclonal antibodies.
Patel D; Bassi R; Hooper AT; Sun H; Huber J; Hicklin DJ; Kang X
Anticancer Res; 2008; 28(5A):2679-86. PubMed ID: 19035294
[TBL] [Abstract][Full Text] [Related]
4. Reduction of human melanoma tumor growth in severe combined immunodeficient mice by passive transfer of antibodies induced by a high molecular weight melanoma-associated antigen mimotope vaccine.
Wagner S; Krepler C; Allwardt D; Latzka J; Strommer S; Scheiner O; Pehamberger H; Wiedermann U; Hafner C; Breiteneder H
Clin Cancer Res; 2008 Dec; 14(24):8178-83. PubMed ID: 19088033
[TBL] [Abstract][Full Text] [Related]
5. Improved tumor immunity using anti-tyrosinase related protein-1 monoclonal antibody combined with DNA vaccines in murine melanoma.
Saenger YM; Li Y; Chiou KC; Chan B; Rizzuto G; Terzulli SL; Merghoub T; Houghton AN; Wolchok JD
Cancer Res; 2008 Dec; 68(23):9884-91. PubMed ID: 19047169
[TBL] [Abstract][Full Text] [Related]
6. CR011, a fully human monoclonal antibody-auristatin E conjugate, for the treatment of melanoma.
Tse KF; Jeffers M; Pollack VA; McCabe DA; Shadish ML; Khramtsov NV; Hackett CS; Shenoy SG; Kuang B; Boldog FL; MacDougall JR; Rastelli L; Herrmann J; Gallo M; Gazit-Bornstein G; Senter PD; Meyer DL; Lichenstein HS; LaRochelle WJ
Clin Cancer Res; 2006 Feb; 12(4):1373-82. PubMed ID: 16489096
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of human tumor growth by IgG2A monoclonal antibodies correlates with antibody density on tumor cells.
Herlyn D; Powe J; Ross AH; Herlyn M; Koprowski H
J Immunol; 1985 Feb; 134(2):1300-4. PubMed ID: 3965572
[TBL] [Abstract][Full Text] [Related]
8. A melanosomal membrane protein is a cell surface target for melanoma therapy.
Takechi Y; Hara I; Naftzger C; Xu Y; Houghton AN
Clin Cancer Res; 1996 Nov; 2(11):1837-42. PubMed ID: 9816138
[TBL] [Abstract][Full Text] [Related]
9. Human monoclonal antibody to tumor-associated ganglioside GD2.
Katano M; Saxton RE; Irie RF
J Clin Lab Immunol; 1984 Nov; 15(3):119-26. PubMed ID: 6099419
[TBL] [Abstract][Full Text] [Related]
10. A cell surface 230 kDa protein from murine melanoma involved with tumor malignancy.
Mendes PF; Xander P; Novaes e Brito RR; Mortara RA; Jasiulionis MG; Lopes JD
Cancer Lett; 2008 Apr; 262(2):276-85. PubMed ID: 18226856
[TBL] [Abstract][Full Text] [Related]
11. Antitumor activity of humanized monoclonal antibody against HM1.24 antigen in human myeloma xenograft models.
Kawai S; Yoshimura Y; Iida S; Kinoshita Y; Koishihara Y; Ozaki S; Matsumoto T; Kosaka M; Yamada-Okabe H
Oncol Rep; 2006 Feb; 15(2):361-7. PubMed ID: 16391855
[TBL] [Abstract][Full Text] [Related]
12. The novel chimeric anti-NCAM (neural cell adhesion molecule) antibody ch.MK1 displays antitumor activity in SCID mice but does not activate complement-dependent cytolysis (CDC).
Klehr M; Koehl U; Mühlenhoff M; Tawadros S; Fischer T; Schomäcker K; Heuckmann JM; Bochennek K; Jensen M
J Immunother; 2009 Jun; 32(5):442-51. PubMed ID: 19609236
[TBL] [Abstract][Full Text] [Related]
13. Binding activities and antitumor properties of a new mouse/human chimeric antibody specific for GD2 ganglioside antigen.
Alvarez-Rueda N; Leprieur S; Clémenceau B; Supiot S; Sébille-Rivain V; Faivre-Chauvet A; Davodeau F; Paris F; Barbet J; Aubry J; Birklé S
Clin Cancer Res; 2007 Sep; 13(18 Pt 2):5613s-5620s. PubMed ID: 17875797
[TBL] [Abstract][Full Text] [Related]
14. Therapeutic antitumor efficacy of monoclonal antibody against Claudin-4 for pancreatic and ovarian cancers.
Suzuki M; Kato-Nakano M; Kawamoto S; Furuya A; Abe Y; Misaka H; Kimoto N; Nakamura K; Ohta S; Ando H
Cancer Sci; 2009 Sep; 100(9):1623-30. PubMed ID: 19555390
[TBL] [Abstract][Full Text] [Related]
15. Interferon-alpha enhances CD317 expression and the antitumor activity of anti-CD317 monoclonal antibody in renal cell carcinoma xenograft models.
Kawai S; Azuma Y; Fujii E; Furugaki K; Ozaki S; Matsumoto T; Kosaka M; Yamada-Okabe H
Cancer Sci; 2008 Dec; 99(12):2461-6. PubMed ID: 19032371
[TBL] [Abstract][Full Text] [Related]
16. Enhancement of antibody-dependent mechanisms of tumor cell lysis by a targeted activator of complement.
Imai M; Ohta R; Varela JC; Song H; Tomlinson S
Cancer Res; 2007 Oct; 67(19):9535-41. PubMed ID: 17909064
[TBL] [Abstract][Full Text] [Related]
17. A novel class of antitumor antibodies: nucleosome-restricted antinuclear autoantibodies (ANA) from healthy aged nonautoimmune mice.
Iakoubov LZ; Torchilin VP
Oncol Res; 1997; 9(8):439-46. PubMed ID: 9436197
[TBL] [Abstract][Full Text] [Related]
18. In vivo and in vitro production and detection of monoclonal antibodies to surface components on metastatic variants of murine tumor cells.
Miner KM; Reading CL; Nicolson GL
Invasion Metastasis; 1981; 1(3):158-74. PubMed ID: 6897920
[TBL] [Abstract][Full Text] [Related]
19. Defucosylated anti-CCR4 monoclonal antibody exerts potent ADCC against primary ATLL cells mediated by autologous human immune cells in NOD/Shi-scid, IL-2R gamma(null) mice in vivo.
Ito A; Ishida T; Utsunomiya A; Sato F; Mori F; Yano H; Inagaki A; Suzuki S; Takino H; Ri M; Kusumoto S; Komatsu H; Iida S; Inagaki H; Ueda R
J Immunol; 2009 Oct; 183(7):4782-91. PubMed ID: 19748990
[TBL] [Abstract][Full Text] [Related]
20. Tumor-localized ligation of CD3 and CD28 with systemic regulatory T-cell depletion induces potent innate and adaptive antitumor responses.
Lee CH; Chiang YH; Chang SE; Chong CL; Cheng BM; Roffler SR
Clin Cancer Res; 2009 Apr; 15(8):2756-66. PubMed ID: 19318495
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
